Mekanistic Therapeutics

Mekanistic Therapeutics

Mekanistic Therapeutics designs and discovers anti-cancer agents that inhibit multiple cancer drivers.  Our lead agent, MTX-211 is a potent and selective dual inhibitor of two frequently aberrant cancer drivers. It is effective against a number of cancer types generally resistant to monotherapy alone.

Location:
Ann Arbor

Management:
Christopher Whitehead, PhD and Judith Sebolt-Leopold, PhD

Visit the Website